Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | May 23, 2023 | May 24, 2023 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | September 16, 2023 | September 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,095 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 4,190 · Balance 15,095 F1: Restricted stock units granted on May 23, 2023. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on May 23, 2023. Price not applicable.
Syros Pharmaceuticals, Inc.
Report date September 16, 2023 · Filed September 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,666 |
Reported balance
After 2023-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-16 · Exercise / conversion · Acquired 2,666 · Balance 3,666 F1: Represents shares of common stock received upon vesting of a restricted stock unit award. F2: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,334 |
Reported balance
After 2023-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-16 · Exercise / conversion · Disposed 2,666 · Balance 5,334 F3: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F4: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon vesting of a restricted stock unit award.
F2: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F4: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-11-20 · Grant · Acquired 25,696 · Balance 246,962 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 2 · 2019-11-20 · Grant · Acquired 45,119 · Balance 292,081 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 3 · 2019-11-20 · Grant · Acquired 74,414 · Balance 366,495 F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Row 4 · 2019-11-20 · Disposition to issuer · Disposed 366,495 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 6,252 · Balance 0 F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.96 · Expires 2022-03-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 10,994 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.47 · Expires 2022-04-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 8,326 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.70 · Expires 2022-07-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 8,326 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.68 · Expires 2022-10-31 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 8,326 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.22 · Expires 2022-12-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.48 · Expires 2023-01-28 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 12,488 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.24 · Expires 2023-04-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 17,738 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.33 · Expires 2023-07-29 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 17,738 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.12 · Expires 2023-10-28 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-20 · Disposition to issuer · Disposed 17,738 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.56 · Expires 2023-12-02 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-11-20 · Disposition to issuer · Disposed 19,688 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.30 · Expires 2024-02-03 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2019-11-20 · Disposition to issuer · Disposed 17,738 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.64 · Expires 2024-07-28 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2019-11-20 · Disposition to issuer · Disposed 20,350 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.10 · Expires 2024-10-27 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2019-11-20 · Disposition to issuer · Disposed 10,175 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2024-12-19 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2019-11-20 · Disposition to issuer · Disposed 15,670 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.57 · Expires 2025-02-02 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2019-11-20 · Disposition to issuer · Disposed 10,175 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $109.90 · Expires 2025-05-04 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2019-11-20 · Disposition to issuer · Disposed 8,625 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $132.56 · Expires 2025-07-27 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-11-20 · Disposition to issuer · Disposed 8,625 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.08 · Expires 2025-11-09 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2019-11-20 · Disposition to issuer · Disposed 8,625 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.80 · Expires 2026-02-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2019-11-20 · Disposition to issuer · Disposed 8,625 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.97 · Expires 2026-05-02 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2019-11-20 · Disposition to issuer · Disposed 29,669 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.69 · Expires 2026-08-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2019-11-20 · Disposition to issuer · Disposed 29,669 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option is fully exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F2: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F3: This option is fully exercisable.
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.60 · Expires 2031-05-23 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.64 · Expires 2031-06-02 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 209 · Balance 0 F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 17,131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 10 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,131 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 59,234 | $0.00 Strike: $71.43 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 9 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,234 shares Expires 2028-10-29 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 59,234 | $0.00 Strike: $88.91 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 8 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,234 shares Expires 2028-07-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 59,234 | $0.00 Strike: $83.13 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 7 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,234 shares Expires 2028-05-08 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 33,881 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 6 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,881 shares Expires 2028-01-29 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 33,881 | $0.00 Strike: $100.97 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 5 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,881 shares Expires 2027-10-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 33,881 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,881 shares Expires 2027-07-31 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 33,880 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 3 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,880 shares Expires 2027-05-01 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 29,669 | $0.00 Strike: $113.18 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 2 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,669 shares Expires 2027-01-30 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:31 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 29,669 | $0.00 Strike: $102.18 | $0.00 |
DisclosureSEC source: 0001415889-19-001378 · form4-11222019_071117.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,669 shares Expires 2026-10-31 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 15,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000509 · form4-05062019_040519.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,608 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 6,620 | $95.21 | $630,290.20 |
DisclosureSEC source: 0001415889-19-000509 · form4-05062019_040519.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,266 Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 15,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000509 · form4-05062019_040519.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionPerformance Stock Unit · Derivative | 33,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000253 · form4-03052019_040328.xml · derivative · entry 5 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 115,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000253 · form4-03052019_040328.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,755 Underlying: Common Stock · 115,755 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F3 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 13,900 | $85.96 | $1,194,844.00 |
DisclosureSEC source: 0001415889-19-000253 · form4-03052019_040328.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,278 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 33,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000253 · form4-03052019_040328.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The performance stock units granted to the reporting person on January 28, 2019 vested and settled for shares of the Company's common stock. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 18,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-19-000133 · form4-02062019_040201.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantPerformance Stock Unit · Derivative | 33,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000106 · form4-01302019_040102.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,809 Underlying: Common Stock · 33,809 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F2 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019. F2 · derivative.exercise_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019. F2 · derivative.expiration_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on March 1, 2019. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:25 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 8,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001769 · form4-12182018_031258.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:25 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 3,876 | $68.20 | $264,343.20 |
DisclosureSEC source: 0001415889-18-001769 · form4-12182018_031258.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,369 Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:25 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 8,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001769 · form4-12182018_031258.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 59,234 | $0.00 Strike: $71.43 | $0.00 |
DisclosureSEC source: 0001415889-18-001565 · form4-10312018_041001.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,234 Underlying: Common Stock · 59,234 shares Expires 2028-10-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 29, 2019. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 59,234 | $0.00 Strike: $88.91 | $0.00 |
DisclosureSEC source: 0001415889-18-001205 · form4-08012018_040824.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,234 Underlying: Common Stock · 59,234 shares Expires 2028-07-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. Read SEC document |
| May 09, 2018 Filed May 17, 2018 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | PurchaseCommon Stock | 1,208 | $82.60 | $99,784.42 |
DisclosureSEC source: 0001415889-18-000763 · form4-05172018_010518.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,316 Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 30,079 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000763 · form4-05172018_010518.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,079 Underlying: Common Stock · 30,079 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (Right to Buy) · Derivative | 59,234 | Not disclosed Strike: $83.13 | Not disclosed |
DisclosureSEC source: 0001415889-18-000763 · form4-05172018_010518.xml · derivative · entry 3 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,234 Underlying: Common Stock · 59,234 shares Expires 2028-05-08 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal installments, commencing on May 8, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000695 · form4-05082018_010518.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,519 | $86.89 | $131,985.91 |
DisclosureSEC source: 0001415889-18-000695 · form4-05082018_010518.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,108 Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000695 · form4-05082018_010518.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · CEO, CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011401 · doc4.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,060 | $95.26 | $196,235.60 |
DisclosureSEC source: 0001209191-18-011401 · doc4.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,127 Read SEC document |
| February 17, 2018 Filed Feb 20, 2018 17:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011401 · doc4.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 16:06 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantPerformance Stock Unit · Derivative | 7,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010348 · doc4.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,283 Underlying: Common Stock · 7,283 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the Company's common stock. F2 · price: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.exercise_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. F2 · derivative.expiration_date: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan and will vest on February 17, 2018. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 16:47 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | PurchaseCommon Stock | 3,260 | $91.90 | $299,594.00 |
DisclosureSEC source: 0001209191-18-008456 · doc4.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,904 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:34 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 33,881 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001209191-18-006220 · doc4.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Underlying: Common Stock · 33,881 shares Expires 2028-01-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest as follows: 8,470 shares on January 29, 2019; 8,470 shares on January 29, 2020; 8,470 shares on January 29, 2021; and 8,471 shares on January 29, 2022. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:02 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066617 · doc4.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:02 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 2,094 | $107.06 | $224,183.64 |
DisclosureSEC source: 0001209191-17-066617 · doc4.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,644 Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:02 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066617 · doc4.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 33,881 | Not disclosed Strike: $100.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-058427 · doc4.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Underlying: Common Stock · 33,881 shares Expires 2027-10-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 33,881 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001209191-17-046928 · doc4.xml · derivative · entry 5 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Underlying: Common Stock · 33,881 shares Expires 2027-07-31 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046928 · doc4.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,932 | $134.10 | $259,081.20 |
DisclosureSEC source: 0001209191-17-046928 · doc4.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,188 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:48 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046928 · doc4.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:18 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 17,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029185 · doc4.xml · derivative · entry 2 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,131 Underlying: Common Stock · 17,131 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:18 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 33,880 | $0.00 Strike: $124.06 | $0.00 |
DisclosureSEC source: 0001209191-17-029185 · doc4.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,880 Underlying: Common Stock · 33,880 shares Expires 2027-05-01 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:07 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 6,643 | $117.02 | $777,363.86 |
DisclosureSEC source: 0001209191-17-011555 · doc4.xml · nonDerivative · entry 2 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,920 Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:07 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantCommon Stock | 14,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011555 · doc4.xml · nonDerivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,563 F1 · shares: Represents shares of common stock relating to the 2014-2016 Long Term Incentive Plan and issued under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:19 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 29,669 | Not disclosed Strike: $113.18 | Not disclosed |
DisclosureSEC source: 0001209191-17-006355 · doc4.xml · derivative · entry 1 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,669 Underlying: Common Stock · 29,669 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 16:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 6,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153641 · doc4.xml · derivative · entry 4 Alles Mark J · CIK 0001538897 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 2, 2013 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.